Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from CMS, Boosting Payment Rate to $854

Cardio Diagnostics received a final gapfill payment rate of $854 from CMS for its AI-driven cardiovascular tests, Epi+Gen CHD and PrecisionCHD. This rate is higher than the preliminary rates of $350 for Epi+Gen CHD and $684.76 for PrecisionCHD. The finalized rate will be effective for claims with dates of service on or after January 1, 2026. Cardiovascular disease remains the leading cause of death in the US, with over 700,000 deaths in 2022, and Cardio Diagnostics aims to expand access to its advanced cardiovascular tests for Medicare beneficiaries.